Search hospitals
>
Pennsylvania
>
Philadelphia
Fox Chase Cancer Center
Claim this profile
Philadelphia, Pennsylvania 19111
Global Leader in Lung Cancer
Global Leader in Cancer
Conducts research for Pancreatic Cancer
Conducts research for Breast Cancer
Conducts research for Prostate Cancer
1153 reported clinical trials
68 medical researchers
Summary
Fox Chase Cancer Center is a medical facility located in Philadelphia, Pennsylvania. This center is recognized for care of Lung Cancer, Cancer, Pancreatic Cancer, Breast Cancer, Prostate Cancer and other specialties. Fox Chase Cancer Center is involved with conducting 1,153 clinical trials across 668 conditions. There are 68 research doctors associated with this hospital, such as Anthony J. Olszanski, Jessica Bauman, MD, Margaret von Mehren, MD, and Hossein Borghaei.
Area of expertise
Lung Cancer
Fox Chase Cancer Center has run 181 trials for Lung Cancer. Some of their research focus areas include:
Cancer
Fox Chase Cancer Center has run 157 trials for Cancer. Some of their research focus areas include:
Top PIs
Anthony J. Olszanski
Fox Chase Cancer Center
4 years of reported clinical research
Jessica Bauman, MD
Fox Chase Cancer Center
4 years of reported clinical research
Margaret von Mehren, MD
Fox Chase Cancer Center
4 years of reported clinical research
Hossein Borghaei
Fox Chase Cancer Center
6 years of reported clinical research
Clinical Trials running at Fox Chase Cancer Center
Cancer
Lung Cancer
Skin Cancer
Prostate Cancer
Bladder Cancer
Ovarian Cancer
Solid Tumors
Multiple Myeloma
Colorectal Cancer
Breast Cancer
Intensified Post-Surgery Monitoring
for Cancer Surgery Recovery
This is a randomized trial of intensified post-discharge surveillance (Intervention Arm) versus standard post-discharge surveillance (Control Arm).
Recruiting
2 awards
Phase 3
Pembrolizumab
for Advanced Cancers
The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-up Phase or 3) Second Course Phase. Each participant will transition to this extension study in one of the following three phases, depending on the study phase they were in at the completion of the parent study. Participants who were in the First Course Phase of study treatment with pembrolizumab or lenvatinib in their parent study will enter the First Course Phase of this study and complete up to 35 doses or more every 3 weeks (Q3W) or 17 doses or more every 6 weeks (Q6W) of study treatment with pembrolizumab or a pembrolizumab-based combination or lenvatinib according to arm assignment. Participants who were in the Follow-up Phase in the parent study (post-treatment or Survival Follow-up Phase) will enter the Survival Follow-up Phase of this study. Participants who were in the Second Course Phase in their parent study will enter Second Course Phase of this study and complete up to 17 doses Q3W or 8 doses Q6W of study treatment with pembrolizumab or a pembrolizumab-based combination according to arm assignment. Any participant originating from a parent trial where crossover to pembrolizumab was permitted upon disease progression may be eligible for 35 doses as Q3W or 17 doses Q6W of pembrolizumab (approximately 2 years), if they progress while on the control arm and pembrolizumab is approved for the indication in the country where the potential eligible crossover participant is being evaluated.
Recruiting
2 awards
Phase 3
4 criteria
Immunotherapy + Chemotherapy
for Sarcoma
This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with dedifferentiated liposarcoma (DDLPS), undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma that has spread from where it first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill tumor cells. It also blocks a certain enzyme needed for cell division and DNA repair. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding immunotherapy (pembrolizumab) to the standard chemotherapy (doxorubicin) may help patients with metastatic or unresectable DDLPS, UPS or a related poorly differentiated sarcoma live longer without having disease progression.
Recruiting
2 awards
Phase 3
10 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Fox Chase Cancer Center?
Fox Chase Cancer Center is a medical facility located in Philadelphia, Pennsylvania. This center is recognized for care of Lung Cancer, Cancer, Pancreatic Cancer, Breast Cancer, Prostate Cancer and other specialties. Fox Chase Cancer Center is involved with conducting 1,153 clinical trials across 668 conditions. There are 68 research doctors associated with this hospital, such as Anthony J. Olszanski, Jessica Bauman, MD, Margaret von Mehren, MD, and Hossein Borghaei.
Where is Fox Chase Cancer Center located?
**Fox Chase Cancer Center Location and Directions:** - **Address:** 333 Cottman Avenue, Philadelphia, PA 19111. - **By Car:** Accessible via I-76 E, exit 346A for PA-63 W towards Wynnefield. - **Public Transportation:** Buses and trains serve the area, with detailed directions on the center's website.
Who should I call to ask about financial aid or insurance network?
**Fox Chase Cancer Center Financial Assistance and Insurance Information:** - **Financial Assistance:** For charity care and other financial assistance, contact 888-336-5897 or visit the website. Financial counselors are available Monday through Friday, 8 am to 5 pm. For billing questions regarding hospital stays or services on or after October 1, 2022, call 888-336-5897. For services before this date, call 888-378-0357. - **Insurance Inquiries:** Contact the Patient Financial Services Department at 888-366-5897 before your visit to confirm participation with your insurance. - **Additional Support:** Temple Health hospitals, including Fox Chase Cancer Center, offer free or reduced-priced care for qualifying individuals and assistance with government-funded insurance programs and ACA Marketplace Plans.
What insurance does Fox Chase Cancer Center accept?
Fox Chase Cancer Center accepts a wide range of health insurance plans, such as Aetna, HMO, PPO, and POS. Patients are advised to contact their insurance company to understand their benefits and liabilities. This center stands out for accepting all insurance, ensuring broad access for patients.
What awards or recognition has Fox Chase Cancer Center received?
Fox Chase Cancer Center, located in Philadelphia, Pennsylvania, is a National Cancer Institute-designated Comprehensive Cancer Center renowned for its pioneering research and exceptional patient care. It has been honored with two Nobel Prizes, a Kyoto Prize, and a Lasker Prize, highlighting the significant achievements of its staff. Furthermore, it is recognized as one of the top cancer hospitals in the United States by U.S. News & World Report.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.